Table 2.
Parameter | DFS |
OS |
||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RR | 95% CI | df | χ2 | P | RR | 95% CI | df | χ2 | P | |||||||||
RR | ||||||||||||||||||
ErbB-2 | 1.30 | 0.91 to 1.85 | 1.54 | 1.09 to 2.31 | ||||||||||||||
P-ErbB-2 | 1.39 | 0.88 to 2.18 | 1.56 | 0.97 to 2.52 | ||||||||||||||
Medium dose | ||||||||||||||||||
ErbB-2 × CAF | 1.26 | 0.73 to 1.99 | 1.18 | 0.69 to 2.03 | ||||||||||||||
P-ErbB-2 × CAF | 1.11 | 0.60 to 2.08 | 0.83 | 0.42 to 1.63 | ||||||||||||||
High dose | ||||||||||||||||||
ErbB-2 × CAF | 0.56 | 0.33 to 0.96 | 0.34 | 0.22 to 0.71 | ||||||||||||||
P-ErbB-2 × CAF | 0.72 | 0.37 to 1.42 | 0.55 | 0.25 to 1.16 | ||||||||||||||
Likelihood-ratio tests | ||||||||||||||||||
ErbB-2 | 1 | 2.13 | .14 | 1 | 5.85 | .016 | ||||||||||||
P-ErbB-2 | 1 | 2.02 | .15 | 1 | 3.32 | .069 | ||||||||||||
ErbB-2 × CAF | 2 | 8.35 | .015 | 2 | 14.97 | .0006 | ||||||||||||
P-ErbB-2 × CAF | 2 | 1.77 | .41 | 2 | 2.58 | .28 |
NOTE. Variables included in the multivariate model included dose, square of the number of positive axillary lymph nodes, tumor size, menopausal status, and ErbB-2 or P-ErbB-2 status. For ErbB-2 immunohistochemical assay, n = 910. ErbB-2×CAF and P-ErbB-2 × CAF indicate tests of the interaction of ErbB-2 and P-ErbB-2 status, respectively (as dichotomous variables), with dose of CAF. Bold font indicates statistical significance.
Abbreviations: DFS, disease-free survival; OS, overall survival; RR, risk ratio; CAF, cyclophosphamide, doxorubicin, and fluorouracil.